Validation of Biochemical Biomarker Assays used in Drug Discovery and Development: A Review of Challenges and Solutions

Predictive Approaches in Drug Discovery and Development: Biomarkers and In Vitro/In Vivo Correlations

Volumn , Issue , 2012, Pages 23-48

  Szekely Klepser, Gabriella ^a   Fountain, Scott ^b  

^a ALLERGAN INC   (United States)

^b PFIZER INC   (United States)

Author keywords

Biochemical biomarker assay validation; Drug discovery, development; LC MS MS assays; Total cholesterol, and LDL C

Indexed keywords

EID: 84886515547     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118230275.ch2     Document Type: Chapter

References (41)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
2. Mendosa D. History of blood glucose meters. http://www.mendosa.com/history.htm. Accessed 2009 Sep 17.
3. Diabetes Control and Complications (DCCT) report: the effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993;329:977-986.
4. Nambi V, Ballantyne CM. Role of biomarkers in developing new therapies for vascular disease. World J Surg 2007;31:676-681.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
6. Mackay M, Street S, McCall J. Risk reduction in drug discovery and development. Curr Top Med Chem 2005;5:1087-1090.
7. Miller R, Ewy W, Corrigan BW, Ouellet D, Herman D, Kowalski KG, Lockwood P, Koup JR, Donevan S, El-Kattan A, Li CSW, Werth JH, Feltner DE, Lalonde R. How modeling and simulations have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn 2005;32(2):185-197.
8. Pillai GC, Mentre F, Steimer J-L. Non-linear mixed effect modeling- From methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn 2005;32(2):161-183.
9. Barrett JF, Gupta M, Mondick JT. Model-based drug development applied to oncology. Expert Opin Drug Discov 2007;2(2):185-209.
10. Sarker D, Workman P. Pharmacodynamic biomarker for molecular cancer therapeutics. Adv Cancer Res 2007;96:213-268.
11. Sultana SR, O'Connel D, Roblin D. Translational research in the pharmaceutical industry: from theory to reality. Drug Discov Today 2007;12(9,10):419-425.
12. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fitfor- purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007;81(1):104-107.
13. U.S. Department of Health and Human Services, Food and Drug Administration. 2006. Innovation-Stagnation, Critical Path Opportunities List. Available at http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default.htm Accessed 2009 Sep 17.
14. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997;61(3):275-291.
15. Lee JW, Weiner RS, Sailstad JM, Bowsher RR, Knuth DW, O'Brien PJ, Fourcroy JL, Dixit R, Pandite L, Pietrusko RG, Soares HD, Quarmby V, Vesterqvist OL, Potter DM, Witliff JL, Frichte HA, O'Leary T, Perlee L, Kadam S, Wagner JA. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res 2005;22(4):499-511.
16. Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, Keller S, Weinry I, Green M, Duan L, Rogers JA, Millham R, O'Brien PJ, Sailstad J, Khan M, Ray C, Wagner JA. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006;23(2):312-328.
17. Lee JW, Figeys D, Vasilescu J. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. Adv Cancer Res 2007;96:269-298.
18. Parker TS, McNamara DJ, Brown CD, Kolb R, Ahrens EJ Jr, Alberts AW, Tobert J, Chen J, De Schepper PJ. Plasma mevalonate as a measure of cholesterol synthesis in man. J Clin Invest 1984;74:795-804.
19. Li W, Cohen L. Quantitation of endogenous analytes in biofluid without a true blank matrix. Anal Chem 2003;75:5854-5859.
20. Jemal M, Schuster A, Whigan DB. Liquid chromatography/tandem mass spectrometry methods for quantitation of mevalonic acid in human plasma and urine: Method validation, demonstration of using a surrogate analyte, and demonstration of unacceptable matrix effect in spite of use of a stable isotope analog internal standard. Rapid Commun Mass Spectrom 2003;17:1723-1734.
21. King R, Bonfiglio R, Fernandez-Metzler C, Miller-Stein C, Olah T. Mechanistic investigation of ionization suppression in electrospray ionization. J Am Soc Mass Spectrom 2000;11(11):942-950.
22. Li W, Nemirovskiy O, Mathews R, Fountain S, Szekely-Klepser G. Clinical validation of an immunoaffinity LC-MS/MS assay for the quantification of collagen type II neoepitope peptide: a biomarker of MMP activity and osteoarthritis in human urine. Anal Biochem 2007;369(1):41-53.
23. EURACHEM/WELEC Guidance Document No. WGD2 Accreditation for Chemical Laboratories: Guidance on the interpretation of the EN 45000 Series of standards and ISO Guide 25. Laboratory of Government Chemist. Teddington, UK; 1993.
24. International Conference on Harmonization. Validation of analytical methods: definitions and terminology. European Agency for the Evaluation of Medicinal Products; London, UK; 1995.
25. Plotz PH. The autoantibody repertoir: searching for order. Nat Rev Immunol 2003;3:73-78.
26. Baker M. In biomarkers we trust? Nat Biotechnol 2005;23(3):297-304.
27. Wei CM, Lerman A, Rodeheffer RJ, McGregor CJ, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD, Burnett JC Jr. Endothelin in human congestive heart failure. Circulation 1994;89:1580-1586.
28. Kindt E, Shum Y, Badura L, Snyder P, Fountain S, Szekely-Klepser G. Development and validation of an LC/MS/MS procedure for the quantification of endogenous myo-inositol concentrations in rat brain tissue homogenates. Anal Chem 2004;76(16):4901-4908.
29. Szekely-Klepser G, Wade K, Woolson D, Brown R, Fountain S, Kindt E. A validated LC/MS/MS method for the quantification of pyrrole-2,3,5-tricarboxylic acid (PTCA), a eumelanin specific biomarker, in human skin biopsies. J Chromatogr B 2005;826:31-40.
30. Tworoger SS, Hankinson SE. Collection, processing and storage of biological samples in epidemiological studies: sex hormomones, carotenoids, inflammatory markers and proteomics as examples. Canc Epidemiol Biomarkers Prev 2006;15:1578-1581.
31. Fast DM, Kelley M, Viswanathan CT, O'Shaughnessy J, King SP, Chaudhary A, Weiner R, DeStefano AJ, Tang D. Workshop report and follow-up- AAPS Workshop on current topics in GLP bioanalysis: Assay reproducibility for incurred samples-Implications of Crystal City recommendations. AAPS J 2009;11(2):238-241.
32. Pan S, Aebersold R. Quantitative proteomics by stable isotope labeling and mass spectrometry. Method Mol Biol 2006;367:209-218.
33. Gygi SP, Rist B, Gerber SA, Turecek, F., Gelb, MH Aebersold, R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999;17:994-999.
34. Gygi SP, Rist B, Griffin TJ, Eng, J., Aebersold R. Proteome analysis of low-abundance proteins using multi-dimensional chromatography and isotope-coded affinity tags. J Proteome Res 2002;1:47-54.
35. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5:573-588.
36. Ackermann BL, Berna MJ. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev Proteomics 2007;492:175-186.
37. Pavlickova P, Schneider EM, Hug H. Advances in recombinant antibody microarrays. Clin Chim Acta 2004;343(1,2):17-35.
38. duPont N, Wang K, Wadhwa P, Culhane J, Nelson E. Validation and comparison of Luminex multiplex cytokine analysis kits with ELISA: Determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol 2005;66(2):175-191.
39. Liu MY, Xydakis AM, Hoogeveen RC, Jones PH, O'Brian Smith E, Kathleen W. Nelson KW, Ballantyne CM. Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system. Clin Chem 2005;51:1102-1109.
40. St. Ledger K, Agee SJ, Kasaian MT, Forlow SB, Durn BL, Minyard J, Lu QA, Todd J, Vesterqvist O, Burczynski ME, Analytical validation of a highly sensitive microparticle-based immunoassay for the quantitation of IL-13 in human serum using the Erenna® immunoassay system, Journal of Immunological Methods 2009;350:161-170.
41. Heymach JV, Tran HT, Fritsche HA, et al. Lower baseline levels of plasma hepatocyte growth factor (HGF), IL-6, and IL-8 are correlated with greater tumor shrinkage in renal cell carcinoma patients treated with pazopanib using the Q400 Biomarker Workstation. Presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; November Boston, MA. Abstract A11. 2009;15-17.